t(4;11) BCP-ALL首次完全缓解期异基因移植:移植前MRD状态的影响
该注册研究分析2000-2017年151例t(4;11) BCP-ALL患者在首次完全缓解期接受异基因造血干细胞移植的结局,2年无白血病生存率和总生存率分别为51%和60%。移植前MRD阴性是影响生存的最强有利因素,其结局与核型正常患者相似;而移植前MRD阳性者结局劣于核型正常患者。
要点
- t(4;11) BCP-ALL患者首次完全缓解期接受异基因移植,2年LFS为51%、OS为60%。
- 移植前MRD阴性者LFS、OS、RI、NRM均显著优于MRD阳性者。
- 移植前MRD阳性者结局劣于核型正常BCP-ALL,需考虑额外治疗。
核心结论
- t(4;11) BCP-ALL患者在首次完全缓解期接受异基因造血干细胞移植,若移植前MRD阴性则结局与核型正常患者相当,支持移植指征;MRD阳性者结局较差,需移植前额外治疗。
研究设计与样本
- 基于EBMT注册组的回顾性分析,纳入2000至2017年间151例首次完全缓解期接受异基因造血干细胞移植的成人t(4;11) BCP-ALL患者,中位年龄38岁,供者包括HLA相合同胞或无血缘供者。
主要发现
- 151例患者2年无白血病生存率为51%,总生存率为60%,复发率为30%,非复发死亡率为20%。
- 与567例核型正常BCP-ALL患者相比,t(4;11)患者上述结局无显著差异。
- 移植前MRD阴性是LFS(HR=0.2,p<0.001)、OS(HR=0.14,p<0.001)、RI(HR=0.23,p=0.001)和NRM(HR=0.16,p=0.002)的最强有利因素。
- 移植前MRD阴性的t(4;11)患者结局与MRD阴性核型正常BCP-ALL患者相似。
- 移植前可检测到MRD的t(4;11)患者结局劣于核型正常BCP-ALL患者(LFS:27% vs. 50%,p=0.02)。
临床怎么用
- 对于t(4;11) BCP-ALL成人患者,若能在首次完全缓解期达到MRD阴性,应考虑异基因造血干细胞移植。
- 移植前MRD阳性的t(4;11) BCP-ALL患者预后较差,需在移植前追加治疗以争取MRD转阴。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adult B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with t(4;11)(q21;q23);KMT2A/AFF1 is a poor-prognosis entity. This registry-based study was aimed to analyze outcome of patients with t(4;11) BCP-ALL treated with allogeneic hematopoietic stem cell transplantation (alloHSCT) in first complete remission (CR1) between 2000 and 2017, focusing on the impact of measurable residual disease (MRD) at the time of transplant. Among 151 patients (median age, 38) allotransplanted from either HLA-matched siblings or unrelated donors, leukemia-free survival (LFS) and overall survival (OS) at 2 years were 51% and 60%, whereas relapse incidence (RI) and non-relapse mortality (NRM) were 30% and 20%, respectively. These results were comparable to a cohort of contemporary patients with diploid normal karyotype (NK) BCP-ALL with equivalent inclusion criteria (n = 567). Among patients with evaluable MRD pre-alloHSCT, a negative status was the strongest beneficial factor influencing LFS (hazard ratio [HR] = 0.2, p < 0.001), OS (HR = 0.14, p < 0.001), RI (HR = 0.23, p = 0.001), and NRM (HR = 0.16, p = 0.002), with a similar outcome to MRD-negative NK BCP-ALL patients. In contrast, among patients with detectable pretransplant MRD, outcome in t(4;11) BCP-ALL was inferior to NK BCP-ALL (LFS: 27% vs. 50%, p = 0.02). These results support indication of alloHSCT in CR1 for t(4;11) BCP-ALL patients, provided a negative MRD status is achieved. Conversely, pre-alloHSCT additional therapy is warranted in MRD-positive patients.
引用
- Esteve J, Giebel S, Labopin M, et al. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. Leukemia. 2021. PMID: 33542481. doi:10.1038/s41375-021-01135-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。